OTCMKTS:IGXT IntelGenx Technologies Q4 2023 Earnings Report $0.17 0.00 (0.00%) As of 04/25/2025 Earnings History IntelGenx Technologies EPS ResultsActual EPS-$0.02Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AIntelGenx Technologies Revenue ResultsActual Revenue$0.43 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AIntelGenx Technologies Announcement DetailsQuarterQ4 2023Date3/21/2024TimeN/AConference Call DateThursday, March 21, 2024Conference Call Time8:30AM ETUpcoming EarningsIntelGenx Technologies' next earnings date is estimated for Tuesday, May 13, 2025, based on past reporting schedules. Conference Call ResourcesConference Call AudioConference Call TranscriptInterim ReportEarnings HistoryCompany ProfilePowered by IntelGenx Technologies Q4 2023 Earnings Call TranscriptProvided by QuartrMarch 21, 2024 ShareLink copied to clipboard.There are 9 speakers on the call. Operator00:00:00Greetings. Welcome to the IntelGenx Fourth Quarter and Full Year 2023 Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. Operator00:00:25I will now turn the conference over to your host, Stephen Kilmer, Investor Relations at IntelGenx. Speaker 100:00:33Good morning, everyone, and thank you for joining us on today's call. With me on the line are Dwight Gorham, IntelGenx's CEO Andre Godin, our President and CFO Doctor. Frank Pietrantonio, our Director of Clinical Research and Tommy Kenny, our Senior Vice President and General Counsel. Before we begin, I would like to remind you that all amounts mentioned today are in U. S. Speaker 100:00:57Dollars unless otherwise mentioned, and today's call may contain forward looking information that represents our expectations as of today and accordingly are subject to change. We do not undertake any obligation to update any forward looking statements except as may be required by U. S. And Canadian securities laws. A number of assumptions were made by us in preparing these forward looking statements, which are subject to risks and results may differ materially. Speaker 100:01:22Details on these risks and assumptions can be found in our filings with the U. S. And Canadian Securities Commissions. I would now like to turn the call over to Mr. Gorham. Speaker 100:01:30Dwight? Speaker 200:01:32Thank you, Steve. Good morning, everyone, and thank you for joining us for the IntelGenx Q4 and full year 2023 conference call. On today's call, I will provide a corporate update and discuss the progress we have made on our key pipeline projects consistent with what we have previously committed to shareholders. Then Andre will review our financial results. Following that, we will open up the line for your questions. Speaker 200:02:01I will now update you on our key programs, beginning with RIZAPORT. During the Q3 of 2023, we received the 1st purchase order for the RIZAPORT, the U. S. Market name for RIZAPORT from our commercial customer Gensco Pharma. This represents a significant milestone for the company as it was our first purchase order for the commercial supply of a pharmaceutical oral film. Speaker 200:02:31We commenced production in December 2023 and expect to ship the ordered reza film product to Gensco in Q2 2024 for immediate launch to market. Unfortunately, as of the end of 2023, we saw no appreciable progress by Axaltas, our partner for RIZAPORT in Spain. Consequently, by mutual agreement with Axaltas, we have jointly started the process of finding a new commercial partner with production promotion capabilities ideally suited to maximize RIZAPORT's commercial success on the European market and expand the product's commercial availability in EU markets beyond Spain. Turning to our buprenorphine buccal film program, we understand from Xyremed, the agent and affiliate of our co development partner, Chemo Research, that is still in discussion with the FDA regarding the amended abbreviated new drug application submitted to the agency in September. We will of course update investors on the status of the ANDA as additional information becomes available. Speaker 200:03:48Now turning to our cannabis business, we are happy we have entered into a settlement agreement with Tilray in November. The settlement included a purchase order for 3 new products, namely CBD-twenty, THC-ten and a 10.10 combined CBD THC. Due to subsequent requests by Tilray, we should be in a position to complete the updated formulation work by May, June and the products will then be scheduled for production and delivery. Turning to Animal Health, we are delighted to advance that important business via development and licensing agreements signed in December with a wholly owned subsidiary of Covenant Animal Health. Under the terms of the development agreement, Covenant Animal Health will fund development and manufacturing of the beta film based drug product. Speaker 200:04:48The license agreement will give Covenant Animal Health exclusive rights to exploit the product in the field for non human applications. In return, IntelGenx will receive royalties on a worldwide net sales of the product. Ahead of commercialization, IntelGenx will manufacture the product on a worldwide basis for clinical development. The parties also anticipate entering into a subsequent commercial supply agreement pursuant to which IntelGenx will supply the product to Covenant Animal Health. As much as we are excited by this current partnership with an industry leader like Covenant Health, we also think that it could important revenue inflection point for our overall Vethafilm business. Speaker 200:05:37Covenant is a well recognized player in the space and as such, the partnership should help open the doors to several additional commercial opportunities for proprietary VITASILM drug delivery platform as it advances towards becoming a standard administration method for companion animals in the future. In support of that, last month we unveiled very encouraging results from a Vethafilm proof of concept study, which was conducted through a research collaboration with UPEI, 1 of North America's leading veterinary universities. As we have discussed in the past, the reliable administration of medications to dogs and cats is a concern for many owners and veterinarians. As I am sure many of you can test, there are few prescription medications that dogs and cats will legally accept and forced administration of capsules, tablets and liquids may be stressful for both the pet and its owner or owners. Additionally, many owners report that medicating the pet becomes more difficult with each dose, often leading to decreased owner compliance, missed doses and potentially treatment failures. Speaker 200:06:54The purpose of the research collaboration with UPEI was to assess palatability, owner perceived acceptability and ease of administration of the vet of healthy dogs and cats. Specifically, the study evaluated 1, exception rate of various VEDAFILM placebo formulations in dogs and cats at first exposure 2, preference between flavors of VidaFilm placebo formulations in dogs and cats 3, changes in acceptance rates over longer periods and 4, owner perception of ease of administration and acceptance and other behaviors associated with Betafilm placebo formulations. Overall, 100% of dog owners and 57% of cat owners felt the administration of better films oral films was very easy or easy. And 95% of dog owners and 82% of cat owners identified Fetaphilm as the preferred method of medication administration. Moving on to R and D, we have completed dosing in the Buna montelukast Versafilm 2A clinical trial in patients with mild to moderate Alzheimer's disease this month and expect to report initial trial results next quarter. Speaker 200:08:21Additionally, having now received approvals from the Swedish Medical Products Agency, the Swedish Ethical Review Authority and the Regional Biobank Center to conduct the Montparnc Montelukast Versafil Phase 2 clinical trial in patients with Parkinson's disease, we currently expect dosing in the study to be initiated before the end of the current quarter. The multicenter, randomized, double blinded, placebo trial, which is designed to assess Montelukast versafilm as an alternative to the tablet form of montelukast will be conducted at the Karolinska University Hospital in collaboration with Principal Investigator, Doctor. Per Sevingtson, who will sponsor the study through a Swedish Research Council grant worth approximately $2,000,000 Finally, earlier this month, the Phase 1b trial for our oral transmucosal formulation of DMT was initiated. The Phase 1b study is designed to evaluate the relative safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized film formulation compared to an intravenous EMT. Top line results for the Phase 1b study are expected in the second half of this year. Speaker 200:09:45With that, I would like to turn the call over to Andre for a review of our financial results. Andre? Speaker 300:09:52Thank you, Dwight. Good morning, everyone. As Dwight mentioned, I'll take a few minutes to discuss the company's financial performance for the 4th quarter as well as the full year fiscal year ended December 31, 2023. For the 4th quarter, the total revenue amounted to $426,000 an increase of 146% over $173,000 for the same 3 month period last year. The change is mainly attributable to an increase in R and D revenue. Speaker 300:10:31Our operating costs and expenses were $2,400,000 for Q4 2023 versus 2.7 $1,000,000 for the corresponding 3 month period of 2022. For Q4 2023, the company had an operating loss of $2,000,000 down from $2,500,000 in Q4 2022 as well as adjusted EBITDA, which was negative $1,700,000 for Q4 2023, a similar improvement over negative $2,300,000 for Q4 2022. Our net comprehensive loss improved to $1,700,000 or $0.01 on a basic and diluted per share basis for Q4 2023 compared to $2,300,000 or $0.01 per basic and diluted share for the comparable year of 2022. For the full year of 2023, total revenue amounted to $1,039,000 compared to $950,000 for 2022. The full year operating costs were $10,500,000 for 2023 versus $10,400,000 for 2022. Speaker 300:11:53For the full year 2023, the company had an operating loss of $9,500,000 dollars compared to an operating loss of $9,400,000 for the comparable period of 2022. Net comprehensive loss was $10,100,000 or $0.06 per basic and diluted shares for 2023 compared to $11,500,000 or $0.07 per basic and diluted share for the comparable period of 2022, an improvement of $1,400,000 As of December 31, 2023, the company's cash and short term investments totaled $2,300,000 Subsequent to the year end, IntelGenx announced the launch of a Reg A offering of up to 2,000,000 shares of non traded Series A convertible cumulative preferred stock at an offering price of $10 per share for maximum offering amount of $20,000,000 dollars As we've discussed in the past, we're always trying to balance our financing needs with the goal of limiting current shareholders' solution as much as possible. After exploring several potential financing opportunities and structures in the current market of small cap and micro cap health care companies, we feel this offering provides us with the best opportunity to raise funds at a valuation that we believe is more reflective of our assets and business prospects. As we mentioned in our press release announcing the offering, with the pending U. Speaker 300:13:40S. Commercial launch of RIZA Film next quarter, we will be entering into a phase of anticipated rapid growth. This raise will allow us to support that while we also continue to make strategic investments in the advancement of the rest of our product pipeline and service portfolio. I will now turn the call back to Dwight. Speaker 200:14:07Thanks, Andre. We are looking forward to continuing to execute on our key programs and to deliver on the upcoming milestones we have discussed today. To reiterate, they are 1, the launch of the RIZA Film in the USA 2, finding a new commercial partner for the RIZA port in Spain and additional markets in Europe 3, reporting initial results of the Phase 2 Buna Monte Lucas Versafilm trial in moderate to mild Alzheimer's disease 4, initiating subject dosing in the Mont Park, Montelukast Versafilm Phase 2 clinical trial in patients with Parkinson disease and 5, completing our Reg A preferred share offering. Finally, speaking of our services business, I'm pleased to report that the new development project pipeline is highly active with several parties having confirmed interest in IntelGenx performing development work on their behalf on a fee for service basis. We expect to initiate 3 to 5 new development projects under the CDMO business model during the course of the 2024, and our new business development efforts are on their way to accomplishing this goal. Speaker 200:15:28With that, I will now turn the call over for questions. I would like to remind you that our forward looking statements apply to both our prepared remarks and the following Q and A. Thank you. Operator00:16:27Your first question for today is from Hugh Kiely, a Private Investor. Speaker 400:16:33Good morning, Dwight, Andre, Frank and Tommy. Good update, Dwight, on the activities of IntelGenx. Just wondering would Speaker 500:16:44give a little bit of an overview of the rollout Speaker 400:16:47of RIZZIFILM to the pharmacies in Q2? Speaker 200:16:55I'm sorry, Kyle. Hugh, you broke up a little bit. You're asking me for the what's the rollout plan for the pharmacy? Speaker 400:17:04Yes, that would be if you could share that, that would be great because I've been checking my local pharmacies. They just say it's coming, but couldn't give a specific date. Speaker 200:17:19That actually should happen sometime, I'm guessing, and I'm not talking on behalf of Gensco because they control the final date when that goes. Sometime in the month of May, I suspect, but that's a professional opinion based on when I'm going to ship the product. Speaker 400:17:35Okay. That's good. And is there any further update of any additional countries beyond At this point, for the reason, no, Hugh. Speaker 200:17:54At this point for the reason, no, Hugh. As I said, our focus right now is finding a new partner that will service the 5 major markets in Europe at this point. We're placing our Spanish person who was supposed to be able to reach the 5 the big 5 in Europe. Speaker 400:18:14Okay. Thank you for that response. And any update on the progress of Todatokol? I know there was on the plan for that with the irritation study? Speaker 200:18:34There is no further update on that. We're still going still working on that, but still issues to be resolved. Speaker 400:18:42Okay. And returning back to VISITILM or progress on the pediatric film submission to the FDA? Speaker 200:18:54Nadine, do you want to handle that? Speaker 600:18:59Yes. So the pediatric film, the 5 milligram will be manufactured with the validation batches. And then we need stability data before submission. So most probably later this year. Speaker 400:19:13Okay. Okay. Thank you for that. And just a little bit overview with the BELBUCA with the FDA. Is any major issues in that, Dwight? Speaker 400:19:25Or do you think those are just sit down and clarification issues? Speaker 200:19:32I know that the customer, the partner is in discussion with the FDA and we're expecting communication in that regard in a relative short term in the next 3 to 4 or 5 weeks. But at this point, I don't know that there's I don't know what the issues are, Hugh. It's really between Cyramed and the FDA. And as soon as they know, they'll let us know. And if it's announceable, I will absolutely be transparently with that. Speaker 200:20:07Us. Speaker 400:20:08Okay. And before I go back in the queue, with the Endo bankruptcy plan proved any insights into the status of the future of the product? Speaker 200:20:28I very recently had further conversations with representatives from Endo. And those discussions are early in the game plan, but we're looking to find a path forward for specifically the specific product you're referring to. But at this point, I have no clarity on what's absolutely required. We have partners looking for it. We have potentially someone who may be interested in automating a deal for it, but that's way too immature for us to comment further. Speaker 400:21:15Okay. I appreciate that comment. And with the Montelukast trial ending, is the submission to the what do you call it, neutral party that does all the data analysis when the data comes back if positive, which we expect, then would the data be rolled out or seek a partner first? I know it's kind of a strategic question, but everyone's really watching that. Speaker 200:21:52Well, it depends on what the date is, and how it looks. We get the date in May. And depending on that, if it's good there, there's a meeting with health authorities, etcetera, to establish what the clinical and regulatory strategies need to Speaker 100:22:05be to move it forward. Speaker 200:22:08But at this point, we're still waiting we do not have the data yet. It's all being numbers are being crunched, but it's not available. Speaker 400:22:18Okay. Last question on the 2 way products is, is it possible to be able to that going to Canada or is that going to some other global countries? Speaker 200:22:30Are you still talking Montelukastian? Sorry. Speaker 400:22:32No. The Tilway, the 3 products you developed developing for Tilway, is that for Canada? Speaker 200:22:41Yes, those are for Canada. Speaker 400:22:44For Canada. All right. Last of my questions, loxapine, is that any chance of that progressing forward? Is that still in the queue pending all the other activities you have going on? Speaker 200:23:01Well, it's a twofold piece to loxapine. 1, it's in the Q because there's other things we're focusing on. And B, the market does not appear strong in the U. S. At this point for that product. Speaker 700:23:14Okay. Speaker 200:23:16We're trying to sort that part out. Speaker 400:23:20Okay. Thank you, Dwight. And good very good progress report, especially with all the activities in the better film and the CDMO world that you indicated prior quarters. Thank you, Dwight. Speaker 200:23:35Yes. Thank you for the questions, Steve. Operator00:23:39Your next question for today is from Brent Gaethje, a Private Investor. Speaker 700:23:45Good morning all. Just a couple of questions. Do you have any revenue projections on the Tilray products? Speaker 200:23:56Andre, do you want to handle that? Speaker 300:23:58Yes. I mean, the initial order is for 400 1,000 films. So it's and also the revenue would roughly be anywhere between $200,000 $300,000 but we're expecting some repeat. But for the initial order, that would be the revenue the expected revenue. Speaker 700:24:33Okay. And then do you all have any projections on Resafilm? I know you all said you all anticipate rapid growth, but I mean do you have any idea what that looks like? Speaker 300:24:48Yes. I mean, unfortunately, we don't give the guidance, but what we can say is that what the initial forecast was determined by Gensco seems to be very conservative based on our latest discussions. So we're expecting these numbers to be much better, but we still need to wait and see how the launch will go and how the repeat orders will come in. But it could be very decent revenue, but since we don't really give guidance, I don't want to show up numbers here, but it will be several $1,000,000 of revenue for sure. Yes. Speaker 700:25:53Okay. And then given that with this latest round of financing, once that's completed and the other projects in the fold generating revenue, do you expect that to be the last time you'll need to raise money? Speaker 300:26:13For technically, if everybody everything goes accordingly for Riza, we'll know a little bit more about BELBUCA or buprenorphine in the short term. It should be, but there will be some expansion in terms of our facility to come at some point because if the volume that we are told that we will have to manufacture for both RIZAFIM and especially buprenorphine, we might be running out of capacity sometimes in 2025 or 2026. So there could be an expansion, but that would probably not be funded through equity. We're looking at different scenario, maybe bank loan, government support, maybe a partnering support. So there are different ways that we're looking at it. Speaker 300:27:20Most likely, we wouldn't have to raise equity. But that's where we think we are at this point, but it will depend on obviously, on the launch date and the numbers that we've been told. If they meet those numbers, we might be facing that sooner than later. Speaker 700:27:46Okay. Well, that would be a good thing if that happened. Thank you, guys. Speaker 200:27:50Absolutely. Speaker 300:27:51Thank you. Thank you. Operator00:27:56Your next question is from Abraham Shapiro, a private investor. Speaker 500:28:01Hey, good morning. Congratulations. I'm excited to going forward. I'm still looking for more revenue. A couple of my questions were really asked, but as far as the walking away from Axalta, they held us up for you guys up for a couple of years now. Speaker 500:28:23Is there legal issues finding a new partner? Are they obligated in any way that they didn't perform their agreement? Speaker 200:28:39I'll let Tommy comment if I don't fill in the blanks properly, but I do not believe there's any legal obligation on their part. And I know are there any barriers to us finding a new partner. In fact, Axaltis will work with us to help identify the partners. They'll be active in the identification part, but not the selection of the partners. Speaker 500:29:05Okay. A couple of my questions were already asked. But the in regard to Benefil, when the approval process for veterinary products, is that quicker than the is it FDA or another body? How does that work when we finally get some product? Speaker 200:29:29The approval process should be slightly quicker. I'll let Nadine comment on whether it's similar to the FDA process, just I believe a bit shorter. Speaker 600:29:43It is an FDA The requirements are highly similar to what we do for human. So we should expect something very similar to what we see for new drug approval. Speaker 500:29:55The new drug. So when do we when can we see a better film product getting approved to market? Speaker 600:30:04That's highly dependent on the partner and the speed at which they run the requirement in terms of clinical and stability studies for the Speaker 200:30:19shouldn't expect it to happen in the next it's not going to happen in the next 2 years. Okay. It was likely Speaker 500:30:282 years. So that's the long term short term, but long term. And what about Speaker 200:30:38Short term, there's good development revenue in there. But commercial revenue will be beyond 2 years. Speaker 500:30:47Beyond 2 years, all right. And what about after the Parkinson's study, if that's proved successful, what's the next what do we do next with that? Speaker 200:31:00Well, as I said, we sit down with the agencies and review the data to understand what's required for the next phase and the clinicals in the next phase. And then like in all likeliness, you would potentially look for a partnership opportunity for the product. Speaker 500:31:19And the same was with Montelukast, you had good results from we have any partnership potential with that one going on? Speaker 200:31:33At this point, no, we're sitting waiting for the data. I mean, everybody's Speaker 500:31:39kind of Speaker 200:31:40on pins and needles waiting to see what the data pull looks like. Speaker 500:31:45All right. Best of luck going forward with the rates as well. That's it. All I got. Speaker 200:31:54We certainly want we certainly when we know what the data looks like, we'll be looking to ensure that everybody understands we've got good news or bad news, one way or the other. Speaker 500:32:06Again, when is that expected? Speaker 200:32:09We should get the data by the end of May. Speaker 500:32:12End of May. All right. Good luck with that. That's all I got. Thank you. Speaker 300:32:17Thanks, Abe. Operator00:32:21Your next question is a follow-up question from Hugh Kiley. Speaker 400:32:26Yes. Thank you for taking my follow-up question. With the Tuohy, the initial three products, do you anticipate further orders for them or any of the products under development with Tilray? Speaker 200:32:42I think Andre specifically said we do anticipate the potential for further follow-up orders on these three products. And as of this date, there's been no advanced conversations on additional products. Operator00:33:07Your next question is from Trevor Lee, a Private Investor. Speaker 800:33:13Hello. Thanks for taking my call. I was curious if you had any just like results from the raise like how far along you are or if you were going to do the full $20,000,000 before closing it or would you close it earlier kind of what's the update there? Speaker 200:33:35Andre, you want to take that? Speaker 300:33:37Yes, thanks. Yes, we started the process and it's a digital offering. So it's mostly happening online And the subscription, everything can be done online. So there's a lot of newsletter, articles that will be published. I mean most of the action or the main spending or exposure will happen in the next, I would say, 2, 3 weeks. Speaker 300:34:16But there is a possibility to have a rolling closing, which means we won't wait till we reach our objective. Our objective is anywhere between 10,000,000 and 20,000,000. We might close when we reach 2,000,000 or 3,000,000 dollars That's the plan anyway. So we have 12 months, but the plan is to probably get everything done by August, latest September. So but as soon as we have made, let's say, dollars 2,000,000 to $3,000,000 we would make a first closing and then continue the process and then close another one. Speaker 300:35:01So we can there's no limit as to how many closing we can do. Speaker 800:35:08Okay. And then Speaker 100:35:11I guess is there any way Speaker 500:35:12to provide just more color Speaker 800:35:13on the CDMO stuff like what kind of some of the potential partnerships and whatnot will entail like is that just packaging their products or is that doing R and D for them or how does that work? Speaker 200:35:27The CDMO specifically is focused on doing the initial development work with the customers and then keeping the manufacturing rights going forward. So the ones that we're in conversation with are all specific molecules where we will do a the vast majority of the development work. They'll do the registrations and we'll keep the manufacturing rights. Speaker 800:36:03Okay. And then are there any products from that that might get launched in the next year or 2? Or do you think it's further out than that if some of the deals go through? Speaker 200:36:14I think they're further out than that. The big deal in the short term for commercial is Riza and the Belbuca. Those are the 2 major focus points on commercial sales. And then the other part is building up the development side of the revenue base that ensures we have manufacturing platform going forward. Speaker 800:36:36Okay. And then on the manufacturing side, do you have like a relative revenue amount kind of that we could pull in with this before expanding, maybe on like an annual basis? Speaker 200:36:52I'm going to refer back to Andre's point that we don't give forward speculation on the sales. So at this point, I'm not in a position to actually make that comment. Speaker 300:37:04Okay. I think that's all I Speaker 800:37:07had for right now. Thank you. Operator00:37:15Your next question is a follow-up question from Hugh Kiely. Speaker 400:37:21Last one, I promise you, is any I've got to keep tabbing my questions. Any update of investment houses issuing a research report based upon the good progress you made over the past couple of years and the path forward? Speaker 200:37:41At this point, I'm not aware of that, Hugh. Maybe Andre is, but I am not. And I think the real focus on management is stick to the knitting, drive the commercial line and fill up the development portfolio for future years of manufacturing. So that's what we're really focused on. But I've not heard that any analyst is going to pick this up yet. Speaker 400:38:05Okay. All right. Thank you. Operator00:38:13We have reached the end of the question and answer session. And I will now turn the call over to Dwight for closing remarks. Speaker 200:38:20Yes. Thank you very much for all of the questions. Hopefully, the answers provide a certain amount of guidance to you. This concludes our Q4 and full year 2023 investor call update. I would once again like to thank the entire Inteligenics team for its hard work and dedication, our Board of Directors for their continued support of the management team, and finally our investors for continuing to believe in and supporting us. Speaker 200:38:45Thank you and goodbye.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallIntelGenx Technologies Q4 202300:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsInterim report IntelGenx Technologies Earnings HeadlinesIntelgenx Technologies (OTC:IGXT) Stock Quotes, Forecast and News SummaryAugust 18, 2024 | benzinga.comIntelGenx Technologies Corp.: IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation ProcessJuly 20, 2024 | finanznachrichten.deHere’s How to Claim Your Stake in Elon’s Private Company, xAIElon Musk has done it again. He’s developed a powerful new AI model that’s already turning heads — and turning the industry upside down. Some say it could threaten Google’s search engine dominance. Others believe it could mark the beginning of the end for ChatGPT.April 26, 2025 | Brownstone Research (Ad)IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation ProcessJuly 19, 2024 | globenewswire.comIntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA' Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer's DiseaseJuly 3, 2024 | globenewswire.comIntelGenx Announces Initiation of the Sale and Investment Solicitation ProcessJune 11, 2024 | globenewswire.comSee More IntelGenx Technologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IntelGenx Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IntelGenx Technologies and other key companies, straight to your email. Email Address About IntelGenx TechnologiesIntelGenx Technologies (OTCMKTS:IGXT), a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.View IntelGenx Technologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Markets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Starbucks (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 9 speakers on the call. Operator00:00:00Greetings. Welcome to the IntelGenx Fourth Quarter and Full Year 2023 Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. Operator00:00:25I will now turn the conference over to your host, Stephen Kilmer, Investor Relations at IntelGenx. Speaker 100:00:33Good morning, everyone, and thank you for joining us on today's call. With me on the line are Dwight Gorham, IntelGenx's CEO Andre Godin, our President and CFO Doctor. Frank Pietrantonio, our Director of Clinical Research and Tommy Kenny, our Senior Vice President and General Counsel. Before we begin, I would like to remind you that all amounts mentioned today are in U. S. Speaker 100:00:57Dollars unless otherwise mentioned, and today's call may contain forward looking information that represents our expectations as of today and accordingly are subject to change. We do not undertake any obligation to update any forward looking statements except as may be required by U. S. And Canadian securities laws. A number of assumptions were made by us in preparing these forward looking statements, which are subject to risks and results may differ materially. Speaker 100:01:22Details on these risks and assumptions can be found in our filings with the U. S. And Canadian Securities Commissions. I would now like to turn the call over to Mr. Gorham. Speaker 100:01:30Dwight? Speaker 200:01:32Thank you, Steve. Good morning, everyone, and thank you for joining us for the IntelGenx Q4 and full year 2023 conference call. On today's call, I will provide a corporate update and discuss the progress we have made on our key pipeline projects consistent with what we have previously committed to shareholders. Then Andre will review our financial results. Following that, we will open up the line for your questions. Speaker 200:02:01I will now update you on our key programs, beginning with RIZAPORT. During the Q3 of 2023, we received the 1st purchase order for the RIZAPORT, the U. S. Market name for RIZAPORT from our commercial customer Gensco Pharma. This represents a significant milestone for the company as it was our first purchase order for the commercial supply of a pharmaceutical oral film. Speaker 200:02:31We commenced production in December 2023 and expect to ship the ordered reza film product to Gensco in Q2 2024 for immediate launch to market. Unfortunately, as of the end of 2023, we saw no appreciable progress by Axaltas, our partner for RIZAPORT in Spain. Consequently, by mutual agreement with Axaltas, we have jointly started the process of finding a new commercial partner with production promotion capabilities ideally suited to maximize RIZAPORT's commercial success on the European market and expand the product's commercial availability in EU markets beyond Spain. Turning to our buprenorphine buccal film program, we understand from Xyremed, the agent and affiliate of our co development partner, Chemo Research, that is still in discussion with the FDA regarding the amended abbreviated new drug application submitted to the agency in September. We will of course update investors on the status of the ANDA as additional information becomes available. Speaker 200:03:48Now turning to our cannabis business, we are happy we have entered into a settlement agreement with Tilray in November. The settlement included a purchase order for 3 new products, namely CBD-twenty, THC-ten and a 10.10 combined CBD THC. Due to subsequent requests by Tilray, we should be in a position to complete the updated formulation work by May, June and the products will then be scheduled for production and delivery. Turning to Animal Health, we are delighted to advance that important business via development and licensing agreements signed in December with a wholly owned subsidiary of Covenant Animal Health. Under the terms of the development agreement, Covenant Animal Health will fund development and manufacturing of the beta film based drug product. Speaker 200:04:48The license agreement will give Covenant Animal Health exclusive rights to exploit the product in the field for non human applications. In return, IntelGenx will receive royalties on a worldwide net sales of the product. Ahead of commercialization, IntelGenx will manufacture the product on a worldwide basis for clinical development. The parties also anticipate entering into a subsequent commercial supply agreement pursuant to which IntelGenx will supply the product to Covenant Animal Health. As much as we are excited by this current partnership with an industry leader like Covenant Health, we also think that it could important revenue inflection point for our overall Vethafilm business. Speaker 200:05:37Covenant is a well recognized player in the space and as such, the partnership should help open the doors to several additional commercial opportunities for proprietary VITASILM drug delivery platform as it advances towards becoming a standard administration method for companion animals in the future. In support of that, last month we unveiled very encouraging results from a Vethafilm proof of concept study, which was conducted through a research collaboration with UPEI, 1 of North America's leading veterinary universities. As we have discussed in the past, the reliable administration of medications to dogs and cats is a concern for many owners and veterinarians. As I am sure many of you can test, there are few prescription medications that dogs and cats will legally accept and forced administration of capsules, tablets and liquids may be stressful for both the pet and its owner or owners. Additionally, many owners report that medicating the pet becomes more difficult with each dose, often leading to decreased owner compliance, missed doses and potentially treatment failures. Speaker 200:06:54The purpose of the research collaboration with UPEI was to assess palatability, owner perceived acceptability and ease of administration of the vet of healthy dogs and cats. Specifically, the study evaluated 1, exception rate of various VEDAFILM placebo formulations in dogs and cats at first exposure 2, preference between flavors of VidaFilm placebo formulations in dogs and cats 3, changes in acceptance rates over longer periods and 4, owner perception of ease of administration and acceptance and other behaviors associated with Betafilm placebo formulations. Overall, 100% of dog owners and 57% of cat owners felt the administration of better films oral films was very easy or easy. And 95% of dog owners and 82% of cat owners identified Fetaphilm as the preferred method of medication administration. Moving on to R and D, we have completed dosing in the Buna montelukast Versafilm 2A clinical trial in patients with mild to moderate Alzheimer's disease this month and expect to report initial trial results next quarter. Speaker 200:08:21Additionally, having now received approvals from the Swedish Medical Products Agency, the Swedish Ethical Review Authority and the Regional Biobank Center to conduct the Montparnc Montelukast Versafil Phase 2 clinical trial in patients with Parkinson's disease, we currently expect dosing in the study to be initiated before the end of the current quarter. The multicenter, randomized, double blinded, placebo trial, which is designed to assess Montelukast versafilm as an alternative to the tablet form of montelukast will be conducted at the Karolinska University Hospital in collaboration with Principal Investigator, Doctor. Per Sevingtson, who will sponsor the study through a Swedish Research Council grant worth approximately $2,000,000 Finally, earlier this month, the Phase 1b trial for our oral transmucosal formulation of DMT was initiated. The Phase 1b study is designed to evaluate the relative safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized film formulation compared to an intravenous EMT. Top line results for the Phase 1b study are expected in the second half of this year. Speaker 200:09:45With that, I would like to turn the call over to Andre for a review of our financial results. Andre? Speaker 300:09:52Thank you, Dwight. Good morning, everyone. As Dwight mentioned, I'll take a few minutes to discuss the company's financial performance for the 4th quarter as well as the full year fiscal year ended December 31, 2023. For the 4th quarter, the total revenue amounted to $426,000 an increase of 146% over $173,000 for the same 3 month period last year. The change is mainly attributable to an increase in R and D revenue. Speaker 300:10:31Our operating costs and expenses were $2,400,000 for Q4 2023 versus 2.7 $1,000,000 for the corresponding 3 month period of 2022. For Q4 2023, the company had an operating loss of $2,000,000 down from $2,500,000 in Q4 2022 as well as adjusted EBITDA, which was negative $1,700,000 for Q4 2023, a similar improvement over negative $2,300,000 for Q4 2022. Our net comprehensive loss improved to $1,700,000 or $0.01 on a basic and diluted per share basis for Q4 2023 compared to $2,300,000 or $0.01 per basic and diluted share for the comparable year of 2022. For the full year of 2023, total revenue amounted to $1,039,000 compared to $950,000 for 2022. The full year operating costs were $10,500,000 for 2023 versus $10,400,000 for 2022. Speaker 300:11:53For the full year 2023, the company had an operating loss of $9,500,000 dollars compared to an operating loss of $9,400,000 for the comparable period of 2022. Net comprehensive loss was $10,100,000 or $0.06 per basic and diluted shares for 2023 compared to $11,500,000 or $0.07 per basic and diluted share for the comparable period of 2022, an improvement of $1,400,000 As of December 31, 2023, the company's cash and short term investments totaled $2,300,000 Subsequent to the year end, IntelGenx announced the launch of a Reg A offering of up to 2,000,000 shares of non traded Series A convertible cumulative preferred stock at an offering price of $10 per share for maximum offering amount of $20,000,000 dollars As we've discussed in the past, we're always trying to balance our financing needs with the goal of limiting current shareholders' solution as much as possible. After exploring several potential financing opportunities and structures in the current market of small cap and micro cap health care companies, we feel this offering provides us with the best opportunity to raise funds at a valuation that we believe is more reflective of our assets and business prospects. As we mentioned in our press release announcing the offering, with the pending U. Speaker 300:13:40S. Commercial launch of RIZA Film next quarter, we will be entering into a phase of anticipated rapid growth. This raise will allow us to support that while we also continue to make strategic investments in the advancement of the rest of our product pipeline and service portfolio. I will now turn the call back to Dwight. Speaker 200:14:07Thanks, Andre. We are looking forward to continuing to execute on our key programs and to deliver on the upcoming milestones we have discussed today. To reiterate, they are 1, the launch of the RIZA Film in the USA 2, finding a new commercial partner for the RIZA port in Spain and additional markets in Europe 3, reporting initial results of the Phase 2 Buna Monte Lucas Versafilm trial in moderate to mild Alzheimer's disease 4, initiating subject dosing in the Mont Park, Montelukast Versafilm Phase 2 clinical trial in patients with Parkinson disease and 5, completing our Reg A preferred share offering. Finally, speaking of our services business, I'm pleased to report that the new development project pipeline is highly active with several parties having confirmed interest in IntelGenx performing development work on their behalf on a fee for service basis. We expect to initiate 3 to 5 new development projects under the CDMO business model during the course of the 2024, and our new business development efforts are on their way to accomplishing this goal. Speaker 200:15:28With that, I will now turn the call over for questions. I would like to remind you that our forward looking statements apply to both our prepared remarks and the following Q and A. Thank you. Operator00:16:27Your first question for today is from Hugh Kiely, a Private Investor. Speaker 400:16:33Good morning, Dwight, Andre, Frank and Tommy. Good update, Dwight, on the activities of IntelGenx. Just wondering would Speaker 500:16:44give a little bit of an overview of the rollout Speaker 400:16:47of RIZZIFILM to the pharmacies in Q2? Speaker 200:16:55I'm sorry, Kyle. Hugh, you broke up a little bit. You're asking me for the what's the rollout plan for the pharmacy? Speaker 400:17:04Yes, that would be if you could share that, that would be great because I've been checking my local pharmacies. They just say it's coming, but couldn't give a specific date. Speaker 200:17:19That actually should happen sometime, I'm guessing, and I'm not talking on behalf of Gensco because they control the final date when that goes. Sometime in the month of May, I suspect, but that's a professional opinion based on when I'm going to ship the product. Speaker 400:17:35Okay. That's good. And is there any further update of any additional countries beyond At this point, for the reason, no, Hugh. Speaker 200:17:54At this point for the reason, no, Hugh. As I said, our focus right now is finding a new partner that will service the 5 major markets in Europe at this point. We're placing our Spanish person who was supposed to be able to reach the 5 the big 5 in Europe. Speaker 400:18:14Okay. Thank you for that response. And any update on the progress of Todatokol? I know there was on the plan for that with the irritation study? Speaker 200:18:34There is no further update on that. We're still going still working on that, but still issues to be resolved. Speaker 400:18:42Okay. And returning back to VISITILM or progress on the pediatric film submission to the FDA? Speaker 200:18:54Nadine, do you want to handle that? Speaker 600:18:59Yes. So the pediatric film, the 5 milligram will be manufactured with the validation batches. And then we need stability data before submission. So most probably later this year. Speaker 400:19:13Okay. Okay. Thank you for that. And just a little bit overview with the BELBUCA with the FDA. Is any major issues in that, Dwight? Speaker 400:19:25Or do you think those are just sit down and clarification issues? Speaker 200:19:32I know that the customer, the partner is in discussion with the FDA and we're expecting communication in that regard in a relative short term in the next 3 to 4 or 5 weeks. But at this point, I don't know that there's I don't know what the issues are, Hugh. It's really between Cyramed and the FDA. And as soon as they know, they'll let us know. And if it's announceable, I will absolutely be transparently with that. Speaker 200:20:07Us. Speaker 400:20:08Okay. And before I go back in the queue, with the Endo bankruptcy plan proved any insights into the status of the future of the product? Speaker 200:20:28I very recently had further conversations with representatives from Endo. And those discussions are early in the game plan, but we're looking to find a path forward for specifically the specific product you're referring to. But at this point, I have no clarity on what's absolutely required. We have partners looking for it. We have potentially someone who may be interested in automating a deal for it, but that's way too immature for us to comment further. Speaker 400:21:15Okay. I appreciate that comment. And with the Montelukast trial ending, is the submission to the what do you call it, neutral party that does all the data analysis when the data comes back if positive, which we expect, then would the data be rolled out or seek a partner first? I know it's kind of a strategic question, but everyone's really watching that. Speaker 200:21:52Well, it depends on what the date is, and how it looks. We get the date in May. And depending on that, if it's good there, there's a meeting with health authorities, etcetera, to establish what the clinical and regulatory strategies need to Speaker 100:22:05be to move it forward. Speaker 200:22:08But at this point, we're still waiting we do not have the data yet. It's all being numbers are being crunched, but it's not available. Speaker 400:22:18Okay. Last question on the 2 way products is, is it possible to be able to that going to Canada or is that going to some other global countries? Speaker 200:22:30Are you still talking Montelukastian? Sorry. Speaker 400:22:32No. The Tilway, the 3 products you developed developing for Tilway, is that for Canada? Speaker 200:22:41Yes, those are for Canada. Speaker 400:22:44For Canada. All right. Last of my questions, loxapine, is that any chance of that progressing forward? Is that still in the queue pending all the other activities you have going on? Speaker 200:23:01Well, it's a twofold piece to loxapine. 1, it's in the Q because there's other things we're focusing on. And B, the market does not appear strong in the U. S. At this point for that product. Speaker 700:23:14Okay. Speaker 200:23:16We're trying to sort that part out. Speaker 400:23:20Okay. Thank you, Dwight. And good very good progress report, especially with all the activities in the better film and the CDMO world that you indicated prior quarters. Thank you, Dwight. Speaker 200:23:35Yes. Thank you for the questions, Steve. Operator00:23:39Your next question for today is from Brent Gaethje, a Private Investor. Speaker 700:23:45Good morning all. Just a couple of questions. Do you have any revenue projections on the Tilray products? Speaker 200:23:56Andre, do you want to handle that? Speaker 300:23:58Yes. I mean, the initial order is for 400 1,000 films. So it's and also the revenue would roughly be anywhere between $200,000 $300,000 but we're expecting some repeat. But for the initial order, that would be the revenue the expected revenue. Speaker 700:24:33Okay. And then do you all have any projections on Resafilm? I know you all said you all anticipate rapid growth, but I mean do you have any idea what that looks like? Speaker 300:24:48Yes. I mean, unfortunately, we don't give the guidance, but what we can say is that what the initial forecast was determined by Gensco seems to be very conservative based on our latest discussions. So we're expecting these numbers to be much better, but we still need to wait and see how the launch will go and how the repeat orders will come in. But it could be very decent revenue, but since we don't really give guidance, I don't want to show up numbers here, but it will be several $1,000,000 of revenue for sure. Yes. Speaker 700:25:53Okay. And then given that with this latest round of financing, once that's completed and the other projects in the fold generating revenue, do you expect that to be the last time you'll need to raise money? Speaker 300:26:13For technically, if everybody everything goes accordingly for Riza, we'll know a little bit more about BELBUCA or buprenorphine in the short term. It should be, but there will be some expansion in terms of our facility to come at some point because if the volume that we are told that we will have to manufacture for both RIZAFIM and especially buprenorphine, we might be running out of capacity sometimes in 2025 or 2026. So there could be an expansion, but that would probably not be funded through equity. We're looking at different scenario, maybe bank loan, government support, maybe a partnering support. So there are different ways that we're looking at it. Speaker 300:27:20Most likely, we wouldn't have to raise equity. But that's where we think we are at this point, but it will depend on obviously, on the launch date and the numbers that we've been told. If they meet those numbers, we might be facing that sooner than later. Speaker 700:27:46Okay. Well, that would be a good thing if that happened. Thank you, guys. Speaker 200:27:50Absolutely. Speaker 300:27:51Thank you. Thank you. Operator00:27:56Your next question is from Abraham Shapiro, a private investor. Speaker 500:28:01Hey, good morning. Congratulations. I'm excited to going forward. I'm still looking for more revenue. A couple of my questions were really asked, but as far as the walking away from Axalta, they held us up for you guys up for a couple of years now. Speaker 500:28:23Is there legal issues finding a new partner? Are they obligated in any way that they didn't perform their agreement? Speaker 200:28:39I'll let Tommy comment if I don't fill in the blanks properly, but I do not believe there's any legal obligation on their part. And I know are there any barriers to us finding a new partner. In fact, Axaltis will work with us to help identify the partners. They'll be active in the identification part, but not the selection of the partners. Speaker 500:29:05Okay. A couple of my questions were already asked. But the in regard to Benefil, when the approval process for veterinary products, is that quicker than the is it FDA or another body? How does that work when we finally get some product? Speaker 200:29:29The approval process should be slightly quicker. I'll let Nadine comment on whether it's similar to the FDA process, just I believe a bit shorter. Speaker 600:29:43It is an FDA The requirements are highly similar to what we do for human. So we should expect something very similar to what we see for new drug approval. Speaker 500:29:55The new drug. So when do we when can we see a better film product getting approved to market? Speaker 600:30:04That's highly dependent on the partner and the speed at which they run the requirement in terms of clinical and stability studies for the Speaker 200:30:19shouldn't expect it to happen in the next it's not going to happen in the next 2 years. Okay. It was likely Speaker 500:30:282 years. So that's the long term short term, but long term. And what about Speaker 200:30:38Short term, there's good development revenue in there. But commercial revenue will be beyond 2 years. Speaker 500:30:47Beyond 2 years, all right. And what about after the Parkinson's study, if that's proved successful, what's the next what do we do next with that? Speaker 200:31:00Well, as I said, we sit down with the agencies and review the data to understand what's required for the next phase and the clinicals in the next phase. And then like in all likeliness, you would potentially look for a partnership opportunity for the product. Speaker 500:31:19And the same was with Montelukast, you had good results from we have any partnership potential with that one going on? Speaker 200:31:33At this point, no, we're sitting waiting for the data. I mean, everybody's Speaker 500:31:39kind of Speaker 200:31:40on pins and needles waiting to see what the data pull looks like. Speaker 500:31:45All right. Best of luck going forward with the rates as well. That's it. All I got. Speaker 200:31:54We certainly want we certainly when we know what the data looks like, we'll be looking to ensure that everybody understands we've got good news or bad news, one way or the other. Speaker 500:32:06Again, when is that expected? Speaker 200:32:09We should get the data by the end of May. Speaker 500:32:12End of May. All right. Good luck with that. That's all I got. Thank you. Speaker 300:32:17Thanks, Abe. Operator00:32:21Your next question is a follow-up question from Hugh Kiley. Speaker 400:32:26Yes. Thank you for taking my follow-up question. With the Tuohy, the initial three products, do you anticipate further orders for them or any of the products under development with Tilray? Speaker 200:32:42I think Andre specifically said we do anticipate the potential for further follow-up orders on these three products. And as of this date, there's been no advanced conversations on additional products. Operator00:33:07Your next question is from Trevor Lee, a Private Investor. Speaker 800:33:13Hello. Thanks for taking my call. I was curious if you had any just like results from the raise like how far along you are or if you were going to do the full $20,000,000 before closing it or would you close it earlier kind of what's the update there? Speaker 200:33:35Andre, you want to take that? Speaker 300:33:37Yes, thanks. Yes, we started the process and it's a digital offering. So it's mostly happening online And the subscription, everything can be done online. So there's a lot of newsletter, articles that will be published. I mean most of the action or the main spending or exposure will happen in the next, I would say, 2, 3 weeks. Speaker 300:34:16But there is a possibility to have a rolling closing, which means we won't wait till we reach our objective. Our objective is anywhere between 10,000,000 and 20,000,000. We might close when we reach 2,000,000 or 3,000,000 dollars That's the plan anyway. So we have 12 months, but the plan is to probably get everything done by August, latest September. So but as soon as we have made, let's say, dollars 2,000,000 to $3,000,000 we would make a first closing and then continue the process and then close another one. Speaker 300:35:01So we can there's no limit as to how many closing we can do. Speaker 800:35:08Okay. And then Speaker 100:35:11I guess is there any way Speaker 500:35:12to provide just more color Speaker 800:35:13on the CDMO stuff like what kind of some of the potential partnerships and whatnot will entail like is that just packaging their products or is that doing R and D for them or how does that work? Speaker 200:35:27The CDMO specifically is focused on doing the initial development work with the customers and then keeping the manufacturing rights going forward. So the ones that we're in conversation with are all specific molecules where we will do a the vast majority of the development work. They'll do the registrations and we'll keep the manufacturing rights. Speaker 800:36:03Okay. And then are there any products from that that might get launched in the next year or 2? Or do you think it's further out than that if some of the deals go through? Speaker 200:36:14I think they're further out than that. The big deal in the short term for commercial is Riza and the Belbuca. Those are the 2 major focus points on commercial sales. And then the other part is building up the development side of the revenue base that ensures we have manufacturing platform going forward. Speaker 800:36:36Okay. And then on the manufacturing side, do you have like a relative revenue amount kind of that we could pull in with this before expanding, maybe on like an annual basis? Speaker 200:36:52I'm going to refer back to Andre's point that we don't give forward speculation on the sales. So at this point, I'm not in a position to actually make that comment. Speaker 300:37:04Okay. I think that's all I Speaker 800:37:07had for right now. Thank you. Operator00:37:15Your next question is a follow-up question from Hugh Kiely. Speaker 400:37:21Last one, I promise you, is any I've got to keep tabbing my questions. Any update of investment houses issuing a research report based upon the good progress you made over the past couple of years and the path forward? Speaker 200:37:41At this point, I'm not aware of that, Hugh. Maybe Andre is, but I am not. And I think the real focus on management is stick to the knitting, drive the commercial line and fill up the development portfolio for future years of manufacturing. So that's what we're really focused on. But I've not heard that any analyst is going to pick this up yet. Speaker 400:38:05Okay. All right. Thank you. Operator00:38:13We have reached the end of the question and answer session. And I will now turn the call over to Dwight for closing remarks. Speaker 200:38:20Yes. Thank you very much for all of the questions. Hopefully, the answers provide a certain amount of guidance to you. This concludes our Q4 and full year 2023 investor call update. I would once again like to thank the entire Inteligenics team for its hard work and dedication, our Board of Directors for their continued support of the management team, and finally our investors for continuing to believe in and supporting us. Speaker 200:38:45Thank you and goodbye.Read morePowered by